Researchers engineered silk fibroin microspheres designed to sequentially release dexamethasone and epidermal growth factor to modulate inflammation and promote repair. In preclinical models, the dual-releasing formulation reduced inflammatory signals and accelerated cutaneous wound closure, with results supporting a controlled-delivery approach for complex healing biology.